Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Intrinsic Value
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. engages in the research, development, processing, wholesale, retail, and manufacturing of Chinese herbal medicines, Chinese patent medicines, Chinese m... [ Read More ]
The intrinsic value of one
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
stock under the Base Case scenario is
31.39
CNY.
Compared to the current market price of 33.12 CNY,
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
is
Overvalued by 5%.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's market capitalization is 25.5B CNY.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock price is 33.12 CNY.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock (31.39 CNY) is 5% less than its price (33.12 CNY).
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock (29.13 CNY) is 12% less than its price (33.12 CNY). Open DCF Valuation
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd stock price (33.12 CNY) is 2% less than its Relative Value (33.66 CNY). Open Relative Valuation
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd has upside potential of 36% compared to the average analyst price target.
Open Wall St Estimates
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd has positive three-year average ROIC (Return on Invested Capital): 10%. The company is efficient at using invested capital to generate operating income.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 10%.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Revenue has dropped by 0% over the past 12 months.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 9% to 10%.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd has positive Net Income for the last twelve months.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd has positive Operating Income for the last twelve months.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's ROE (Return on Equity) has increased in the last 3 years from 12% to 15%.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 15%.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Revenue has been growing by 8% per year for the last 3 years.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd has positive three-year average ROE (Return on Equity): 14%. The company is efficient at transforming stockholders' equity into net income.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Revenue is forecast to grow at a rate of 13% per year over the next 3 years.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd has positive Free Cash Flow for the last twelve months.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's short-term assets (7B CNY) exceed its short-term liabilties (3B CNY).
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd has positive Gross Profit for the last twelve months.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd has negative Net Debt. This means that the company has more cash and short-term investments (2B CNY) than debt (951m CNY).
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's long-term assets (10B CNY) exceed its long-term liabilties (4B CNY).
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's D/E (Debt to Equity) is very low and is equal to 0.14.
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Altman Z-Score is very high and is equal to 6.24.
Valuation Backtest
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Run backtest to discover the historical profit from buying and selling
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Balance Sheet Decomposition
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
| Current Assets | 6.6B |
| Cash & Short-Term Investments | 2B |
| Receivables | 2.7B |
| Other Current Assets | 1.8B |
| Non-Current Assets | 3.7B |
| Long-Term Investments | 1.5B |
| PP&E | 1.5B |
| Intangibles | 396.7m |
| Other Non-Current Assets | 271.2m |
| Current Liabilities | 3.2B |
| Accounts Payable | 615.4m |
| Accrued Liabilities | 336.7m |
| Short-Term Debt | 706.8m |
| Other Current Liabilities | 1.6B |
| Non-Current Liabilities | 396.5m |
| Long-Term Debt | 243.8m |
| Other Non-Current Liabilities | 152.7m |
Earnings Waterfall
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
|
Revenue
|
8.2B
CNY
|
|
Cost of Revenue
|
-4.6B
CNY
|
|
Gross Profit
|
3.6B
CNY
|
|
Operating Expenses
|
-2.8B
CNY
|
|
Operating Income
|
814.8m
CNY
|
|
Other Expenses
|
171.9m
CNY
|
|
Net Income
|
986.7m
CNY
|
Free Cash Flow Analysis
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
According to Wall Street analysts, the average 1-year price target for
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
is 45.17 CNY
with a low forecast of 44.72 CNY and a high forecast of 46.49 CNY.
Shareholder Return
Price
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
| Average Annual Return | 23.22% |
| Standard Deviation of Annual Returns | 46.26% |
| Max Drawdown | -55% |
| Market Capitalization | 25.5B CNY |
| Shares Outstanding | 770 250 076 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. engages in the research, development, processing, wholesale, retail, and manufacturing of Chinese herbal medicines, Chinese patent medicines, Chinese medicine decoction tablets, western medicine preparations, and other medical and health products. The company is headquartered in Tianjin, Tianjin and currently employs 4,650 full-time employees. The company went IPO on 2001-06-06. The firm's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The firm's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.
Contact
IPO
Employees
Officers
The intrinsic value of one
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
stock under the Base Case scenario is
31.39
CNY.
Compared to the current market price of 33.12 CNY,
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
is
Overvalued by 5%.
You don't have any saved screeners yet
